Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
TUCSON, Ariz., April 27, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market close on Thursday, May 10. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | ||
| Date: | Thursday, May 10 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | 866-548-4713 | |
| International: | 323-794-2093 | |
| Conference ID: | 5477857 | |
| Webcast: | http://public.viavid.com/index.php?id=129155 | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
[email protected]
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
[email protected]
